MX2015012604A - Compuesto del éster de ácido guanidinobenzoico. - Google Patents
Compuesto del éster de ácido guanidinobenzoico.Info
- Publication number
- MX2015012604A MX2015012604A MX2015012604A MX2015012604A MX2015012604A MX 2015012604 A MX2015012604 A MX 2015012604A MX 2015012604 A MX2015012604 A MX 2015012604A MX 2015012604 A MX2015012604 A MX 2015012604A MX 2015012604 A MX2015012604 A MX 2015012604A
- Authority
- MX
- Mexico
- Prior art keywords
- acid ester
- trypsin
- guanidinobenzoic acid
- drugs
- kidney disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
Se proporciona un compuesto que es útil como un agente para prevenir y/o tratar enfermedades renales. Medios para la solución Los presentes inventores han estudiado compuestos que tienen una actividad inhibidora de tripsina, y han confirmado que un compuesto de éster de ácido guanidinobenzoico tiene una actividad inhibidora de tripsina, completando así la presente invención. El compuesto de éster de ácido guanidinobenzoico de la presente invención se puede utilizar como un agente para prevenir y/o tratar enfermedades renales (por ejemplo: enfermedad renal crónica, glomerulonefritis aguda, lesión renal aguda y similares) como un agente que sustituirá la terapia de dieta baja en proteínas, y/o como un agente para prevenir y/o tratar enfermedades relacionadas con tripsina(por ejemplo: pancreatitis crónica, enfermedad de reflujo gastroesofágico, encefalopatía hepática, , influenza y similares).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013050011 | 2013-03-13 | ||
| PCT/JP2014/056601 WO2014142219A1 (ja) | 2013-03-13 | 2014-03-13 | グアニジノ安息香酸エステル化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012604A true MX2015012604A (es) | 2016-10-13 |
Family
ID=51536870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012604A MX2015012604A (es) | 2013-03-13 | 2014-03-13 | Compuesto del éster de ácido guanidinobenzoico. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9969709B2 (es) |
| EP (1) | EP2975023B1 (es) |
| JP (1) | JP6314129B2 (es) |
| KR (1) | KR102145649B1 (es) |
| CN (1) | CN105051008B (es) |
| AU (1) | AU2014230583B2 (es) |
| BR (1) | BR112015022762B1 (es) |
| CA (1) | CA2905606C (es) |
| CY (1) | CY1120552T1 (es) |
| DK (1) | DK2975023T3 (es) |
| ES (1) | ES2684045T3 (es) |
| HK (1) | HK1216246A1 (es) |
| HR (1) | HRP20181371T1 (es) |
| HU (1) | HUE039526T2 (es) |
| IL (1) | IL241541B (es) |
| LT (1) | LT2975023T (es) |
| MX (1) | MX2015012604A (es) |
| MY (1) | MY194604A (es) |
| PH (1) | PH12015502023B1 (es) |
| PL (1) | PL2975023T3 (es) |
| PT (1) | PT2975023T (es) |
| RS (1) | RS57568B1 (es) |
| RU (1) | RU2661895C2 (es) |
| SG (2) | SG10201707504VA (es) |
| SI (1) | SI2975023T1 (es) |
| TR (1) | TR201809418T4 (es) |
| TW (1) | TWI666196B (es) |
| UA (1) | UA118668C2 (es) |
| WO (1) | WO2014142219A1 (es) |
| ZA (1) | ZA201506745B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201707504VA (en) | 2013-03-13 | 2017-10-30 | Takeda Pharmaceuticals Co | Guanidinobenzoic acid ester compound |
| US9346776B2 (en) * | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2018080109A (ja) * | 2015-03-16 | 2018-05-24 | 武田薬品工業株式会社 | 治療剤 |
| US10017487B2 (en) | 2015-03-27 | 2018-07-10 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| CN105218289B (zh) * | 2015-10-15 | 2017-08-01 | 浙江大学 | 一种不饱和脂肪酸原位加氢脱羧制备长链烷烃的方法 |
| CN111542511A (zh) | 2017-11-02 | 2020-08-14 | 宇部兴产株式会社 | 蛋白分解酶的双头型抑制剂 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5289640A (en) | 1976-01-21 | 1977-07-27 | Ono Pharmaceut Co Ltd | Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives |
| JPS5753454A (en) | 1980-09-16 | 1982-03-30 | Torii Yakuhin Kk | Guanidinobenzoate and anticomplementary agent |
| AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| JP2886586B2 (ja) | 1989-12-28 | 1999-04-26 | 雪印乳業株式会社 | 新規グアニジノ安息香酸誘導体及びその酸付加塩 |
| US5116985A (en) | 1989-12-28 | 1992-05-26 | Snow Brand Milk Products Co., Ltd. | Isoquinoline derivatives and salts thereof |
| JPH0446148A (ja) | 1990-06-08 | 1992-02-17 | Asahi Chem Ind Co Ltd | ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤 |
| JPH06192085A (ja) | 1992-08-31 | 1994-07-12 | Yuji Inada | ダニアレルギー治療剤 |
| EP0673924A4 (en) | 1992-12-10 | 1996-04-24 | Teikoku Chem Ind Co Ltd | PROPRIONIC ACID DERIVATIVE. |
| JPH0753500A (ja) | 1993-08-16 | 1995-02-28 | Sanwa Kagaku Kenkyusho Co Ltd | グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤 |
| JPH0848664A (ja) | 1994-08-05 | 1996-02-20 | Hisamitsu Pharmaceut Co Inc | 新規なグアニジノ安息香酸エステル誘導体 |
| JPH09124571A (ja) * | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
| WO1997037969A1 (fr) * | 1996-04-10 | 1997-10-16 | Ono Pharmaceutical Co., Ltd. | Inhibiteur de tryptase derives de guanidino |
| JPH10101556A (ja) | 1996-09-27 | 1998-04-21 | Ono Pharmaceut Co Ltd | ファクターｄ阻害剤 |
| JPH10251239A (ja) | 1997-03-14 | 1998-09-22 | Mochida Pharmaceut Co Ltd | 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体 |
| JPH10306025A (ja) | 1997-05-07 | 1998-11-17 | Touin Yokohama Univ | 花粉プロテアーゼ阻害剤 |
| WO2006057152A1 (ja) | 2004-11-08 | 2006-06-01 | Ono Pharmaceutical Co., Ltd. | タンパク質分解酵素阻害化合物からなる糖尿病治療剤 |
| CA2588087A1 (en) | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| ATE401007T1 (de) | 2004-11-26 | 2008-08-15 | Nutricia Nv | Kleinkindernahrung mit proteasehemmer |
| CA2593858A1 (en) | 2005-01-31 | 2006-08-10 | Min Ge | Antidiabetic bicyclic compounds |
| US20090062297A1 (en) | 2006-01-12 | 2009-03-05 | Heidebrecht Richard W | Hydroxyalkylarylamide Derivatives |
| HUE028064T2 (en) | 2007-12-03 | 2016-11-28 | Obe Therapy Biotechnology | Inhibitors of enteropeptidase boropeptide and their use in the treatment of diseases associated with obesity, overweight and / or abnormal fat metabolism |
| ES2532201T3 (es) | 2009-12-07 | 2015-03-25 | Ajinomoto Co., Inc. | Derivado de éster de ácido heteroarilcarboxílico |
| ES2618024T3 (es) | 2011-06-07 | 2017-06-20 | Ea Pharma Co., Ltd. | Derivado de éster de ácido carboxílico heterocíclico |
| IN2014CN01930A (es) * | 2011-09-15 | 2015-09-04 | Astellas Pharma Inc | |
| ES2644962T3 (es) | 2012-01-03 | 2017-12-01 | Oramed Ltd. | Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| EP2964644B1 (en) | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| SG10201707504VA (en) | 2013-03-13 | 2017-10-30 | Takeda Pharmaceuticals Co | Guanidinobenzoic acid ester compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
-
2014
- 2014-03-13 SG SG10201707504VA patent/SG10201707504VA/en unknown
- 2014-03-13 CN CN201480014813.4A patent/CN105051008B/zh active Active
- 2014-03-13 DK DK14763790.4T patent/DK2975023T3/en active
- 2014-03-13 LT LTEP14763790.4T patent/LT2975023T/lt unknown
- 2014-03-13 EP EP14763790.4A patent/EP2975023B1/en active Active
- 2014-03-13 UA UAA201509922A patent/UA118668C2/uk unknown
- 2014-03-13 HU HUE14763790A patent/HUE039526T2/hu unknown
- 2014-03-13 JP JP2015505541A patent/JP6314129B2/ja active Active
- 2014-03-13 TW TW103109057A patent/TWI666196B/zh active
- 2014-03-13 KR KR1020157027906A patent/KR102145649B1/ko active IP Right Grant
- 2014-03-13 WO PCT/JP2014/056601 patent/WO2014142219A1/ja active Application Filing
- 2014-03-13 ES ES14763790.4T patent/ES2684045T3/es active Active
- 2014-03-13 SG SG11201507411TA patent/SG11201507411TA/en unknown
- 2014-03-13 BR BR112015022762-7A patent/BR112015022762B1/pt active IP Right Grant
- 2014-03-13 PL PL14763790T patent/PL2975023T3/pl unknown
- 2014-03-13 CA CA2905606A patent/CA2905606C/en active Active
- 2014-03-13 US US14/775,274 patent/US9969709B2/en active Active
- 2014-03-13 RU RU2015143562A patent/RU2661895C2/ru active
- 2014-03-13 SI SI201430865T patent/SI2975023T1/sl unknown
- 2014-03-13 PT PT147637904T patent/PT2975023T/pt unknown
- 2014-03-13 MY MYPI2015703099A patent/MY194604A/en unknown
- 2014-03-13 TR TR2018/09418T patent/TR201809418T4/tr unknown
- 2014-03-13 RS RS20180861A patent/RS57568B1/sr unknown
- 2014-03-13 MX MX2015012604A patent/MX2015012604A/es active IP Right Grant
- 2014-03-13 AU AU2014230583A patent/AU2014230583B2/en active Active
-
2015
- 2015-09-09 PH PH12015502023A patent/PH12015502023B1/en unknown
- 2015-09-10 IL IL241541A patent/IL241541B/en active IP Right Grant
- 2015-09-11 ZA ZA2015/06745A patent/ZA201506745B/en unknown
-
2016
- 2016-04-13 HK HK16104215.3A patent/HK1216246A1/zh unknown
-
2018
- 2018-08-09 CY CY20181100832T patent/CY1120552T1/el unknown
- 2018-08-27 HR HRP20181371TT patent/HRP20181371T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502023A1 (en) | Guanidinobenzoic acid ester compound | |
| MX362948B (es) | Compuesto del ácido guanidinobenzoico. | |
| CL2013003454A1 (es) | Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| CL2013002612A1 (es) | Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| FR2960542B1 (fr) | Peptide en tant que medicament, en particulier pour le traitement du cancer | |
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
| CO7160102A2 (es) | Fármaco para prevenir y/o tratar la enfermedad renal poliquística | |
| MX2016012318A (es) | Compuesto amidico. | |
| CR20150505A (es) | Derivado de dihidropiridazin-3,5-diona | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| EP3065734A4 (en) | Ferric citrate for reducing cardiac failure in chronic kidney disease patients | |
| MX2015017035A (es) | Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis. | |
| EA201390616A1 (ru) | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 | |
| PH12015500434A1 (en) | Combination of sglt2 inhibitors and anti-hypertensive drugs | |
| MX2016010892A (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica. | |
| WO2013057592A3 (en) | Treatment of sickle cell disease | |
| IL232385A (en) | Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder | |
| MX2015006011A (es) | Pastilla medicinal a base de ibuprofeno sodico dihidratado. | |
| WO2014056779A8 (de) | Arzneimittel zur prophylaxe und behandlung einer neurodegenerativen erkrankung | |
| SG195288A1 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | |
| Jadoul et al. | What are the Causes of the Ill Effects of Chronic Hemodialysis? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED |
|
| FG | Grant or registration |